OBJECTIVE: This study was conducted to examine the safety and efficacy of pioglitazone, a thiazolidinedione insulin sensitizer, in adult outpatients with major depressive disorder. METHOD: In a 12-week, open-label, flexible-dose study, 23 patients with major depressive disorder received pioglitazone monotherapy or adjunctive therapy initiated at 15 mg daily. Subjects were required to meet criteria for abdominal obesity (waist circumference>35 in. in women and >40 in. in men) or metabolic syndrome. The primary efficacy measure was the change from baseline to Week 12 on the Inventory of Depressive Symptomatology (IDS) total score. Partial responders (≥25% decrease in IDS total score) were eligible to participate in an optional extension phase for an additional three months. RESULTS: Pioglitazone decreased depression symptom severity from a total IDS score of 40.3±1.8 to 19.2±1.8 at Week 12 (p<.001). Among partial responders (≥25% decrease in IDS total score), an improvement in depressive symptoms was maintained during an additional 3-month extension phase (total duration=24 weeks) according to IDS total scores (p<.001). Patients experienced a reduction in insulin resistance from baseline to Week 12 according to the log homeostasis model assessment (-0.8±0.75; p<.001) and a significant reduction in inflammation as measured by log highly- sensitive C-reactive protein (-0.87±0.72; p<.001). During the current episode, the majority of participants (74%, n=17), had already failed at least one antidepressant trial. The most common side effects were headache and dizziness; no patient discontinued due to side effects. LIMITATIONS: These data are limited by a small sample size and an open-label study design with no placebo control. CONCLUSION: Although preliminary, pioglitazone appears to reduce depression severity and improve several markers of cardiometabolic risk, including insulin resistance and inflammation. Larger, placebo-controlled studies are indicated.
OBJECTIVE: This study was conducted to examine the safety and efficacy of pioglitazone, a thiazolidinedioneinsulin sensitizer, in adult outpatients with major depressive disorder. METHOD: In a 12-week, open-label, flexible-dose study, 23 patients with major depressive disorder received pioglitazone monotherapy or adjunctive therapy initiated at 15 mg daily. Subjects were required to meet criteria for abdominal obesity (waist circumference>35 in. in women and >40 in. in men) or metabolic syndrome. The primary efficacy measure was the change from baseline to Week 12 on the Inventory of Depressive Symptomatology (IDS) total score. Partial responders (≥25% decrease in IDS total score) were eligible to participate in an optional extension phase for an additional three months. RESULTS:Pioglitazonedecreased depression symptom severity from a total IDS score of 40.3±1.8 to 19.2±1.8 at Week 12 (p<.001). Among partial responders (≥25% decrease in IDS total score), an improvement in depressive symptoms was maintained during an additional 3-month extension phase (total duration=24 weeks) according to IDS total scores (p<.001). Patients experienced a reduction in insulin resistance from baseline to Week 12 according to the log homeostasis model assessment (-0.8±0.75; p<.001) and a significant reduction in inflammation as measured by log highly- sensitive C-reactive protein (-0.87±0.72; p<.001). During the current episode, the majority of participants (74%, n=17), had already failed at least one antidepressant trial. The most common side effects were headache and dizziness; no patient discontinued due to side effects. LIMITATIONS: These data are limited by a small sample size and an open-label study design with no placebo control. CONCLUSION: Although preliminary, pioglitazone appears to reduce depression severity and improve several markers of cardiometabolic risk, including insulin resistance and inflammation. Larger, placebo-controlled studies are indicated.
Authors: An Pan; Michel Lucas; Qi Sun; Rob M van Dam; Oscar H Franco; JoAnn E Manson; Walter C Willett; Alberto Ascherio; Frank B Hu Journal: Arch Intern Med Date: 2010-11-22
Authors: Michael T Heneka; Magdalena Sastre; Lucia Dumitrescu-Ozimek; Anne Hanke; Ilse Dewachter; Cuno Kuiperi; Kerry O'Banion; Thomas Klockgether; Fred Van Leuven; Gary E Landreth Journal: Brain Date: 2005-04-07 Impact factor: 13.501
Authors: Claudia C Kaiser; Dinesh K Shukla; Glenn T Stebbins; Demetrios D Skias; Douglas R Jeffery; Dusan Stefoski; George Katsamakis; Douglas L Feinstein Journal: J Neuroimmunol Date: 2009-05-15 Impact factor: 3.478
Authors: Robert Spanheimer; D John Betteridge; Meng H Tan; Ele Ferrannini; Bernard Charbonnel Journal: Am J Cardiol Date: 2009-06-03 Impact factor: 2.778
Authors: Susan L McElroy; Renu Kotwal; Shishuka Malhotra; Erik B Nelson; Paul E Keck; Charles B Nemeroff Journal: J Clin Psychiatry Date: 2004-05 Impact factor: 4.384
Authors: Jason M Williams; W Anthony Owens; Gregory H Turner; Christine Saunders; Concetta Dipace; Randy D Blakely; Charles P France; John C Gore; Lynette C Daws; Malcolm J Avison; Aurelio Galli Journal: PLoS Biol Date: 2007-10-16 Impact factor: 8.029
Authors: Mohammad Salehi-Sadaghiani; Mehrak Javadi-Paydar; Mohammad Hadi Gharedaghi; Ali Zandieh; Pouria Heydarpour; Yashar Yousefzadeh-Fard; Ahmad Reza Dehpour Journal: Psychopharmacology (Berl) Date: 2012-05-01 Impact factor: 4.530
Authors: Igor Pomytkin; João P Costa-Nunes; Vladimir Kasatkin; Ekaterina Veniaminova; Anna Demchenko; Alexey Lyundup; Klaus-Peter Lesch; Eugene D Ponomarev; Tatyana Strekalova Journal: CNS Neurosci Ther Date: 2018-04-24 Impact factor: 5.243